Advertisement
"There was a great deal of promising new data coming out of WCTRIMS,"according to Dr. Jeff Berk, MedPredict's president. "Following theconference, we were able to interview some of the leading neurologists in MSresearch and gain their perspectives on the more promising new therapies.This report combines their opinions with the research data presented atWCTRIMS to provide MS drug developers with strategic insight for planninggoing forward."
Advertisement
Companies and partnerships discussed in this report include: Abbott,Acorda, Amgen/Epix, Artielle ImmunoTherapeutics, Avigen/Sanochemia, BaroFold,Bayhill, Bayer-Schering, Bayer-Schering/Genzyme, Biogen, Biogen/Elan,Biogen/Genentech/Roche, Biogen/UCB, Daiichi Sankyo, Elan, Genentech,GlaxoSmithKline, GSK/Genmab, GSK/Mitsubishi Tanabe, Lilly/BioMS, MediciNova,Merck-Serono, Novartis, Opexa, PDL/Biogen/Roche, Peptimmune, Roche/Actelion,Roche/Genentech, Sanofi-Aventis, Teva, Teva/Merck-Serono,Teva/Alpharma/Sanofi-Aventis.
This report can be purchased by contacting MedPredict.
About MedPredict
MedPredict (http://www.medpredict.com) maintains a proprietary database ofover 1,000 global physician thought leaders, including 40+ specialties in 30+therapeutic categories. Based on primary interviews with these thoughtleaders, MedPredict publishes periodic reports in each category to keepclients up-to-date on emerging trends and competitive activity. The reportsinclude thought leader reactions to recent publications and medicalconferences, as well as clinical, regulatory and marketing activity.This report provides in-depth analysis of the following topics: -- The trend toward early aggressive therapy, either by earlier use of disease modifying drugs (IFN / GA) or by use of a potent immunosuppressive, followed by maintenance therapy. While most of the Panelists favor early treatment, there is much controversy around "how early" and "what therapy." -- Cost of therapy in the U.S. vs. Latin America. -- Cognitive impairment -- still a significant unmet need in MS. -- PML (progressive multifocal leukoencephalopathy) for VLA-4 and B-cell approaches, and other safety concerns. -- Marketed and new interferons, integrin inhibitors, B-cell inhibitors, vaccines, S1Ps, fumarates, neuroprotection/neuroregeneration, Th-17, cathepsin S, statins, non-immunosuppressants, and Vitamin D. -- Symptomatic benefit.
SOURCE MedPredict
